147 related articles for article (PubMed ID: 21122420)
21. [The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma].
Amano R; Yamada N; Noda E; Kubo N; Tanaka H; Muguruma K; Takashima T; Yashiro M; Maeda K; Onoda N; Sawada T; Nakata B; Ohira M; Ishikawa T; Hirakawa K
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2676-8. PubMed ID: 21224677
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON.
Kudo M; Ikeda M; Takayama T; Numata K; Izumi N; Furuse J; Okusaka T; Kadoya M; Yamashita S; Ito Y; Kokudo N
J Gastroenterol; 2016 Dec; 51(12):1150-1160. PubMed ID: 27106231
[TBL] [Abstract][Full Text] [Related]
23. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.
Wörns MA; Schuchmann M; Düber C; Otto G; Galle PR; Weinmann A
Oncology; 2010; 79(1-2):85-92. PubMed ID: 21071995
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
[TBL] [Abstract][Full Text] [Related]
25. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib.
Ozenne V; Paradis V; Pernot S; Castelnau C; Vullierme MP; Bouattour M; Valla D; Farges O; Degos F
Eur J Gastroenterol Hepatol; 2010 Sep; 22(9):1106-10. PubMed ID: 20300004
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
[TBL] [Abstract][Full Text] [Related]
27. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
[TBL] [Abstract][Full Text] [Related]
28. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.
Cabrera R; Pannu DS; Caridi J; Firpi RJ; Soldevila-Pico C; Morelli G; Clark V; Suman A; George TJ; Nelson DR
Aliment Pharmacol Ther; 2011 Jul; 34(2):205-13. PubMed ID: 21605146
[TBL] [Abstract][Full Text] [Related]
29. [Hepatocellular carcinoma - long-term treatable disease].
Fínek J
Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
[TBL] [Abstract][Full Text] [Related]
30. [Three cases of hepatocellular carcinoma without distant metastasis effectively treated by sorafenib].
Takeda Y; Nakahira S; Takeno A; Suzuki R; Nakata K; Okishiro M; Egawa C; Okamura S; Miki H; Kato T; Takatsuka Y; Tamura S
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2496-8. PubMed ID: 22202425
[TBL] [Abstract][Full Text] [Related]
31. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
[TBL] [Abstract][Full Text] [Related]
32. [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
Turnes J; Díaz R; Hernandez-Guerra M; Gómez M; Castells L; Bustamante J; Espinosa MD; Fernández-Castroagudín J; Serrano T; Rendón P; Andrade R; Salgado M; Arenas J; Vergara M; Sala M; Polo BA; Granizo IM; Gonzálvez ML; Viudez A
Gastroenterol Hepatol; 2015 Apr; 38(4):263-73. PubMed ID: 25583146
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
[TBL] [Abstract][Full Text] [Related]
34. [Influence of body surface area on efficacy and safety of sorafenib in advanced hepatocellular carcinoma].
Kobayashi S; Ohkawa S; Kondo M; Morimoto M; Numata K; Matsunaga K; Okuse C; Suzuki M; Hidaka H; Takada J; Okuwaki Y; Shibuya A; Tanaka K
Gan To Kagaku Ryoho; 2012 Jul; 39(7):1065-70. PubMed ID: 22790040
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
Kawaoka T; Aikata H; Murakami E; Nakahara T; Naeshiro N; Tanaka M; Honda Y; Miyaki D; Nagaoki Y; Takaki S; Hiramatsu A; Waki K; Takahashi S; Chayama K
Oncology; 2012; 83(4):192-200. PubMed ID: 22890083
[TBL] [Abstract][Full Text] [Related]
36. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial.
Sansonno D; Lauletta G; Russi S; Conteduca V; Sansonno L; Dammacco F
Oncologist; 2012; 17(3):359-66. PubMed ID: 22334456
[TBL] [Abstract][Full Text] [Related]
37. Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma.
Yang Y; Lu Y; Wang C; Bai W; Qu J; Chen Y; Chang X; An L; Zhou L; Zeng Z; Lou M; Lv J
Cell Biochem Biophys; 2012 Jun; 63(2):159-69. PubMed ID: 22477032
[TBL] [Abstract][Full Text] [Related]
38. Clinical course of sorafenib treatment in patients with hepatocellular carcinoma.
Woo HY; Heo J; Yoon KT; Kim GH; Kang DH; Song GA; Cho M
Scand J Gastroenterol; 2012 Jul; 47(7):809-19. PubMed ID: 22563643
[TBL] [Abstract][Full Text] [Related]
39. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.
Yau T; Chan P; Ng KK; Chok SH; Cheung TT; Fan ST; Poon RT
Cancer; 2009 Jan; 115(2):428-36. PubMed ID: 19107763
[TBL] [Abstract][Full Text] [Related]
40. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
